

Intellectual Property Prospector

IP Assets Held by Firms In Transition

June 11, 2007
Volume 2, Number 24
Prospector Profiles in this Issue

Company Name	Reference Number	Category Profile
Advanced Technologies Group Ltd.	07.0863	Audit Concerns
Airbee Wireless, Inc.	07.0864	Audit Concerns
Airtrax, Inc.	07.0865	Audit Concerns
American Ammunition, Inc.	07.0866	Audit Concerns
BioLargo, Inc.	07.0867	Audit Concerns
Cardima, Inc.	07.0868	Loss/Deficit
Connected Media Technologies, Inc.	07.0869	Audit Concerns
Cord Blood America, Inc.	07.0870	Audit Concerns
CytoCore, Inc.	07.0871	Audit Concerns
Ecotality, Inc.	07.0872	Audit Concerns
Einstein Noah Restaurant Group, Inc.	07.0873	Loss/Deficit
Enzon Pharmaceuticals, Inc.	07.0874	Loss/Deficit
Glowpoint, Inc.	07.0875	Audit Concerns
GoFish Corporation	07.0876	Audit Concerns
Hendrx Corporation	07.0877	Audit Concerns
ICP Solar Technologies, Inc.	07.0878	Audit Concerns
Imcor Pharmaceutical Company	07.0879	Audit Concerns
Impact Medical Solutions, Inc.	07.0880	Audit Concerns
InforMedix Holdings, Inc.	07.0881	Audit Concerns
Liberty Diversified Holdings, Inc.	07.0882	Audit Concerns
LipidViro Tech, Inc.	07.0883	Audit Concerns
Medlink International, Inc.	07.0884	Audit Concerns
Nanobac Pharmaceuticals, Incorporated	07.0885	Audit Concerns
Naturally Advanced Technologies, Inc.	07.0886	Loss/Deficit
Nayna Networks, Inc.	07.0887	Audit Concerns
NPS Pharmaceuticals, Inc.	07.0888	Loss/Deficit
Orthometrix, Inc.	07.0889	Audit Concerns
Oxford Media, Inc.	07.0890	Audit Concerns

(Click on Reference Number to go directly to Company Profile)

Company Name	Reference Number	Category Profile
Playtex Products, Inc.	07.0891	Low Rating
Premiere Publishing Group, Inc.	07.0892	Loss/Deficit
Protein Polymer Technologies, Inc.	07.0893	Audit Concerns
Pure Vanilla Exchange, Inc.	07.0894	Audit Concerns
Sedona Corporation	07.0895	Audit Concerns
Sipex Corporation	07.0896	Loss/Deficit
Skins, Inc.	07.0897	Audit Concerns
Skylyft Media Networks, Inc.	07.0898	Audit Concerns
The Certo Group Corporation	07.0899	Audit Concerns
The Enlightened Gourmet, Inc.	07.0900	Audit Concerns
The Flooring Zone, Inc.	07.0901	Audit Concerns
Titan Trading Analytics, Inc.	07.0902	Audit Concerns
Torbay Holdings, Inc.	07.0903	Audit Concerns
Town Sports International Holdings, Inc.	07.0904	Loss/Deficit
U.S. Helicopter Corporation	07.0905	Audit Concerns
Worldspace, Inc.	07.0906	Loss/Deficit
XL Generation International, Inc.	07.0907	Audit Concerns
XOMA Ltd.	07.0908	Loss/Deficit

(Click on Reference Number to go directly to Company Profile)

Intellectual Property Prospector identifies companies with total assets of any size filing for bankruptcy or reporting other financial difficulty and profiles their ownership of intellectual property. The Prospector features companies that meet strictly defined, predetermined criteria and is designed to support the efforts of firms and individuals interested in identifying opportunities in the specific area of intellectual property, which includes patents, trademarks, trade secrets, and licenses, among others. Information is compiled weekly and the Prospector is distributed by email every Sunday evening to arrive before 9:00AM every Monday. The Prospector is published by Beard Group, Inc. (<http://BeardGroup.com>). For subscription information call Customer Service at 240-629-3300, ext. 27.

Prospector Profile Selection Criteria:

In order to appear in the **Intellectual Property Prospector**, a company must report ownership of intellectual property assets, as well as one of the conditions listed below:

- An event which indicates financial distress; e.g., default, distressed exchange offer, preferred dividend omission, debt at deep discount, restructuring, low rating, audit concerns, covenant problems, and loss/deficit.
- Chapter 11, 7, or 15 bankruptcy filing
- Section 363 Sales

DISCLAIMER: The conditions for inclusion in the Prospector are selected by the editors, because, in their opinion, the occurrence of such an event or the existence of such a circumstance is a likely indicator of current or prospective financial or operating difficulty. There are, however, other reasons why such facts or circumstances may exist. The inclusion of a profile suggests the possibility of financial distress or the possibility that the company may be of interest to firms and individuals interested in identifying intellectual property for some other reason. *Inclusion should not be construed to represent analysis of the condition of the company or its intellectual property or a definitive determination that the company is in difficulty.*

ACCURACY & COVERAGE: The information contained herein is obtained from sources believed to be reliable. However, the accuracy of most data cannot be verified prior to publication, and the information is not guaranteed. Desired information is often incomplete, inaccurate, delayed or unavailable. Do not rely on the Prospector without independent verification.

SUBSCRIPTIONS: Subscription rate: \$575 for six months, payable in advance. All subscriptions entered are continued until canceled. For subscription information call Customer Service at (240) 629-3300, ext. 27.

Intellectual Property Prospector is a publication of **Beard Group, Inc.**, P. O. Box 4250, Frederick, MD 21705, (240) 629-3300, <http://www.beardgroup.com>. ISSN 1935-3901. Copyright 2007. All rights reserved. Publisher: Christopher Beard.

**Prospector
Profile
07.0863**

Advanced Technologies Group Ltd.

32 Broadway, 3rd Floor
New York, NY 10004
(212) 968-0941

NAICS	511210
Description	Software Publishers
Revenue (mil)	\$1.32
Income (mil)	(\$0.61)
Assets (mil)	\$0.37
Liability (mil)	\$0.12
(for the year ended 1/31/2007)	

Category: Audit Concerns

Event: Donahue Associates, LLC states that during the years ending January 31, 2007 and January 31, 2006, Advanced Technologies Group Ltd. has experienced, and continues to experience, certain going concern issues related to profitability.

Intellectual Property: The Company's success will depend in significant part on certain methodologies it plans to utilize in connection with the commercial applications for its newly acquired technology, as well as with respect to its FX3000 trading system, and on proprietary intellectual property rights it has and may in the future develop. The Company plans to rely on a combination of nondisclosure and other contractual arrangements and trade secrets, copyright, patent and trademark laws to protect its proprietary rights and the proprietary rights of third parties from whom the Company may license intellectual property. The Company also plans to enter into confidentiality agreements with its employees and consultants and limits access to, and distribution of, proprietary information. [SEC Filing 10-KSB 05-04-07]

Description: The Company engages in the development and/or acquisition of new technologies in the e-commerce marketplace. The company owns the FX3000 software system, a Java-based online foreign exchange dealing system.

Officers: Alex Stelmak (Chair, CEO & CFO); Dr. Abel Raskas (Pres., CEO & Dir.); Stan Mashov (VP, CTO & Dir.)

Auditor: Donahue Associates, LLC

Securities: Common Stock-Symbol AVGG>OB; OTC BB;
18,056,673 common shares outstanding as of January 31, 2007.

[Return to top](#)

**Prospector
Profile
07.0864**

Airbee Wireless, Inc.

9400 Key West Avenue
Rockville, Maryland 20850
(301) 517-1860

NAICS	511210
Description	Software Publishers
Employees	52
Revenue (mil)	\$0.13
Income (mil)	(\$4.80)
Assets (mil)	\$0.77
Liability (mil)	\$4.39
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Bagell, Josephs, Levine & Company LLC raised substantial doubt about the ability of Airbee Wireless, Inc. to continue as a going concern due to its operating losses and capital deficits.

Intellectual Property: The Company has filed one patent entitled "System and Method for Data Transmission" (application number 60/502,346) and there are no other patents or copyrights pending at this time. Plans exist for several more patents dealing with the various protocols and features of the software system. The Company believes that its success is more dependent upon technical expertise than proprietary rights. The Company relies upon a combination of patent, copyright, trademark and trade secret laws and contractual restrictions to protect proprietary technology. [SEC Filing 10-KSB 04-17-07]

Description: The Company develops connectivity software for wireless voice and data communications in the United States.

Officers: Raj Sundaesan (Chair, CEO & Dir.); E. Eugene Sharer (Pres., COO & Dir.); VV. Sundaram (Pres. & Managing Dir.); Ram Satagopan (CTO); Mal Gurian (Dir.)

Auditor: Bagell, Josephs, Levine & Company LLC

Securities: Common Stock-Symbol ABEW.OB; OTC BB;
79,029,862 common shares outstanding as of December 31, 2006.

[Return to top](#)

**Prospector
Profile
07.0865**

Airtrax, Inc.

200 Freeway Drive, Unit One
Blackwood, NJ 08012
(856) 232-3000

NAICS		333924
Description		Forklifts Mfg.
Employees		13
Revenue	(mil)	\$1.35
Income	(mil)	(\$4.50)
Assets	(mil)	\$2.88
Liability	(mil)	\$6.05
(for the year ended 12/31/2006)		

Category: Audit Concerns

Event: Robert G. Jeffrey, Certified Public Accountant expressed doubts about the ability of Airtrax, Inc. to continue as a going concern after auditing its financial statements. The auditor points out that the Company had a material working capital deficiency and an accumulated deficit as of December 31, 2006 and has experienced continuing losses.

Intellectual Property: In December 1997, the Company was awarded a patent for an omni-directional helicopter ground-handling device. On January 22, 2002, the Company received US patent #6,340,065 relating to its low vibrations wheels. On May 28, 2002, it received US patent #6,394,203 encompassing certain aspects of the omni-directional wheel with some features specific to the lift truck. In April 15, 2003, the Company received US patent #6,394,203 relating to methods for designing low-vibration wheels. It also has several patent applications pending relating to other aspects of its technology. The Company expects to make future patent applications relating to various other aspects of its omni-directional technology. It also has filed a patent application for its hybrid power module concepts. At this time, no foreign patents have been issued for any of its technology. [SEC Filing 10-KSB 05-02-07]

Description: The Company engages in the development of the omni-directional vehicles for material handling applications in the United States.

Officers: Andrew Guzzetti (Chair); Robert M. Watson (CEO, Acting CFO & Dir.); Nicholas Fenelli (COO); D. Barney Harris (Dir.); James Hudson (Dir.); William Hungerville (Dir.); Fil Filipov (Dir.); Peter Amico, Jr. (Dir.); Robert Borski, Jr. (Dir.)

Auditor: Robert G. Jeffrey, Certified Public Accountant

Securities: Common Stock-Symbol AITX.OB; OTC BB;
24,376,887 common shares outstanding as of April 12, 2007.

[Return to top](#)

**Prospector
Profile
07.0866**

American Ammunition, Inc.

3545 NW 71st Street
Miami, FL 33147
(305) 835-7400

NAICS		332994
Description		Ammunition Mfg.
Employees		45
Revenue	(mil)	\$2.24
Income	(mil)	(\$8.10)
Assets	(mil)	\$2.41
Liability	(mil)	\$2.84
(for the year ended 12/31/2006)		

Category: Audit Concerns

Event: S.W. Hatfield, CPA notes that American Ammunition, Inc. experienced negative gross profit margins, losses from operations and negative cash flows from operations, which raises substantial doubt on its ability to continue as a going concern. Liquidity in prior periods was provided by equity securities sales related to the redemption of a convertible debenture and mandatory exercise of attached warrants. During 2006, the Company retired the outstanding balance on the convertible debenture and cancelled the remaining attached warrants. As a result of this transaction, the auditor states that the Company's "safety net" for future liquidity no longer exists.

Intellectual Property: The Company intends to protect its original intellectual property with patents, copyrights and/or trademarks. The head stamp "A-MERC" was registered as a trademark on May 10, 1994. The Company was assigned a serial number (60/325,046) from the U.S. Patent and Trademark Office for a provisional patent application, filed on September 26, 2001, for a bullet that will not pierce an aircraft fuselage but will penetrate human soft tissue. The October 2004 acquisition of certain intellectual technology property from Triton Ammunition Corporation included the assignment of three patents related to the design and manufacture of certain fragmentable projectiles. [SEC Filing 10-KSB/A 04-30-07]

Description: The Company, through its subsidiaries, engages in the design, manufacture, and sale of small arms ammunition for the wholesale and governmental markets.

Officers: J.A. Fernandez, Sr. (Chair); Andres F. Fernandez (Pres. & CEO); Emilio D. Jara (VP, Sec. & Dir.); Maria A. Fernandez (Dir.)

Auditor: S.W. Hatfield, CPA

Securities: Common Stock-Symbol AAMU.OB; OTC BB;
23,007,902 common shares outstanding as of December 31, 2006.

[Return to top](#)

**Prospector
Profile
07.0867**

BioLargo, Inc.

2603 Main Street, Suite 1155
Irvine, CA 92614
(949) 235-8062

NAICS	541710
Description	Biotechnology
Employees	1
Revenue (mil)	\$0.00
Income (mil)	(\$1.31)
Assets (mil)	\$0.25
Liability (mil)	\$6.11
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Jeffrey S. Gilbert raised substantial doubt about the ability of Biolargo, Inc. to continue as a going concern after auditing its financial statements. The Company had a net loss of \$1,310,706 for the 12-month period ended December 31, 2006, negative cash flow from operating activities of \$1,315,628 for the 12-month period ended December 31, 2006, and an accumulated stockholders' deficit of \$29,539,893 as of December 31, 2006. Also, the auditor points out that the Company had limited liquid and capital resources.

Intellectual Property: On April 30, 2007, the Company completed the acquisition of the BioLargo technology from IOWC Technologies, Inc. (IOWC). Pursuant to the terms of the Asset Purchase Agreement, IOWC sold, transferred and assigned to the Company all of their rights, title and interests to U.S. Patent Number 6,146,725, relating to an absorbent composition to be used in the transport of specimens of bodily fluids; and U.S. Patent Number 6,328,929, relating to method of delivering disinfectant in an absorbent substrate; and related patent applications and national filings. IOWC also transferred all proprietary knowledge, trade secrets, confidential information, computer software and licenses, formulae, designs and drawings, quality control data, processes, methods, inventions and other similar know-how or rights relating to or arising out of the patents. [SEC Filing Filing 10-KSB 05-04-07]

Description: The Company's business strategy is to harness and deliver nature's best disinfectant – iodine – in a safe, efficient, environmentally sensitive and cost-effective manner.

Officers: Dennis Calvert (Chair, Pres., CEO & CFO); Joseph Provenzano (Sec.); Kenneth R. Code (Dir.); Gary Cox (Dir.); Dennis E. Marshall (Dir.)

Auditor: Jeffrey S. Gilbert

Securities: Common Stock-Symbol BLGO.PK; Other OTC; 39,355,166 common shares outstanding as of May 1, 2007.

[Return to top](#)

**Prospector
Profile
07.0868**

Cardima, Inc.

47266 Benicia Street
Fremont, CA 94538
(510) 354-0300

NAICS		339112
Description		Medical Instruments Mfg.
Employees		31
Revenue	(mil)	\$1.54
Income	(mil)	(\$9.53)
Assets	(mil)	\$2.22
Liability	(mil)	\$15.01
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: Cardima, Inc. reported a \$7,023,000 net loss on net sales of \$319,000 for the first quarter ended March 31, 2007, compared with a net loss of \$3,576,000 on net sales of \$384,000 for the same quarter last year. At March 31, 2007, the Company's balance sheet showed \$1,791,000 in total assets and \$21,606,000 in total liabilities, resulting in a \$19,815,000 total stockholders' deficit. The Company's balance sheet also showed strained liquidity with \$1,437,000 in total current assets available to pay \$21,527,000 in total current liabilities.

Intellectual Property: The Company owns 24 issued United States patents and has 5 pending United States patent applications. In December 2000, the Company sold certain patents and related intellectual property pertaining to intravascular sensing and signal detection to Medtronic, Inc., which currently has research efforts in the field of electrophysiology. The Company received a perpetual, worldwide license at no cost from Medtronic to use these patents and related intellectual property in its products for mapping and ablation of arrhythmia-causing tissue. The Company has also licensed a proprietary surface-coating material from another vendor used on certain of its micro-catheters. As of March 31, 2007, the Company has filed 53 patent applications in major international markets, of which 26 have been validated or granted. Under a license agreement with Target Therapeutics, the Company obtained an exclusive, royalty-free, worldwide license under certain patents issued in the U.S. and corresponding international patents to use Target Therapeutics' technology for the diagnosis and treatment of electrophysiological diseases in the body. [SEC Filing 10-KSB 04-17-07]

Description: The Company engages in the design, development, manufacture, and marketing of single-use micro-catheter systems for the diagnosis and treatment of cardiac arrhythmias.

Officers: Gabriel B. Vegh (Chair & CEO)

Auditor: Marc Lumer & Company

Securities: Common Stock-Symbol CRDM.OB; OTC BB;
102,840,963 common shares outstanding as of April 10, 2007.

[Return to top](#)

**Prospector
Profile
07.0869**

Connected Media Technologies, Inc.

80 SW 8th Street, Suite 2230
Miami, FL 33130
(786) 425-0028

NAICS	541990
Description	Media Product Services
Employees	14
Revenue (mil)	\$0.45
Income (mil)	(\$17.49)
Assets (mil)	\$0.71
Liability (mil)	\$4.00
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Salberg & Company, P.A. expressed doubts on the ability of Connected Media Technologies, Inc. to continue as a going concern after auditing its financial statements. The Company has a net loss of \$17,486,292 and net cash used in operations was \$492,848 for the year ended December 31, 2006. In addition, it has working capital deficiency of \$3,872,558, a stockholders' deficiency of \$3,297,062 and an accumulated deficit of \$17,068,859 at December 31, 2006.

Intellectual Property: Through a license agreement with Rothschild Trust Holdings LLC, the Company is the exclusive licensee of United States Patent #6,101,534, "Interactive, Remote, Computer Interface System" and a second patent, "A Media Validation System", U.S. Patent No. 6,952,697. The Company also has certain exclusive rights to several additional patent applications filed with the United States Patent and Trademark Office. In general, the claims of the 534 patent relate to technology that allows multimedia content stored on a removable local media to be "controlled" or "released" for access by the user by visiting a related website on the Internet. [SEC Filing 10-KSB 04-17-07]

Description: The Company, together with its subsidiaries, operates as a digital media and content provider in the United States and internationally.

Officers: Rafael Diaz-Balart (Chair); Robert Rodriguez (Vice Chair); Jeffrey W. Sass (CEO & Dir.); Isidrio Gonzalez (Pres. & Dir.); Mark Mayo (CFO & Dir.)

Auditor: Salberg & Company, P.A.

Securities: Common Stock-Symbol CNCM.OB; OTC BB; 641,907,436 common shares outstanding as of March 31, 2007.

[Return to top](#)

**Prospector
Profile
07.0870**

Cord Blood America, Inc.

9000 West Sunset Boulevard, Suite 400
Los Angeles, CA 90069
(310) 432-4090

NAICS		621511
Description		Medical Laboratories
Employees		5
Revenue	(mil)	\$3.33
Income	(mil)	(\$5.69)
Assets	(mil)	\$0.73
Liability	(mil)	\$6.95
(for the year ended 12/31/2006)		

Category: Audit Concerns

Event: Rose, Snyder & Jacobs raised substantial doubt about the ability of Cord Blood America, Inc. to continue as a going concern after auditing its financial statements. The auditor notes that the Company has sustained recurring operating losses, continues to consume cash in operating activities, and has insufficient working capital and an accumulated deficit at December 31, 2006.

Intellectual Property: Pursuant to a Patent License Agreement, Cord may, on a non-exclusive basis, collect, process and store cord blood utilizing PharmaStem Therapeutics technology and processes covered by its patents for so long as the patents may remain in effect. All of the patents are scheduled to expire in 2010. Cord is obligated under the Patent License Agreement to pay royalties to PharmaStem of 15% of all revenues generated by Cord from the collection and storage of cord blood on and after January 1, 2004. [SEC Filing 10-KSB 04-17-07]

Description: The Company, through its subsidiaries, engages in the collection, testing, processing, and preservation of umbilical cord blood in the United States.

Officers: Matthew L. Schissler (Chair & CEO); Sandra D. Smith (CFO); Noah Anderson (Chief Technology Officer); Joseph R. Vicente (Dir.); Stephen Weir (Dir.); Gayl Rogers Chrysler (Dir.); Timothy McGrath (Dir.)

Auditor: Rose, Snyder & Jacobs

Securities: Common Stock-Symbol CBAI.OB; OTC BB;
49,118,075 common shares outstanding as of April 2, 2007.

[Return to top](#)

**Prospector
Profile
07.0871**

CytoCore, Inc.

414 North Orleans Street, Suite 502
Chicago, IL 60610
(312) 222-9550

NAICS	541710
Description	Biotechnology
Employees	5
Revenue (mil)	\$0.09
Income (mil)	(\$6.57)
Assets (mil)	\$1.28
Liability (mil)	\$4.70
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Amper, Politziner & Mattia, P.C. expressed doubts concerning the ability of CytoCore, Inc. to continue as a going concern due to its recurring losses from operations and resulting dependence upon access to additional external financing.

Intellectual Property: As of December 2006, the Company filed 11 U.S. utility patent applications. In addition, 1 U.S. and 5 foreign patent applications are filed and pending. This group of patents and patent applications covers all aspects of the InPath System including the point of service instrument, the personal and physicians' collectors, and the slide-based test. As a result of the acquisition of AccuMed, the Company acquired 33 issued U.S. patents, 1 U.S. patent application, and 9 foreign patents. In addition, 24 additional foreign patent applications primarily covering the AcCell and AcCell Savant technology and related software were also acquired. The Company owns the trade names "InPath," "e2 Collector," and "Cocktail-CVX." [SEC Filing 10-KSB 04-17-07]

Description: The Company owns Imagent, an ultrasound imaging contrast agent for use in patients with suboptimal echocardiograms.

Officers: Augusto Ocana (CEO); Robert McCullough, Jr. (CFO); Alexander M. Milley (Dir.); John Abeles (Dir.); Clint Severson (Dir.)

Auditor: Amper, Politziner & Mattia, P.C.

Securities: Common Stock-Symbol CYCR.OB; OTC BB;
330,092,335 common shares outstanding as of March 30, 2007.

[Return to top](#)

**Prospector
Profile
07.0872**

Ecotality, Inc.

6821 East Thomas Road
Scottsdale, AZ 85251
(480) 219-5005

NAICS	334413
Description	Fuel Cells Mfg.
Employees	5
Revenue (mil)	\$0.00
Income (mil)	(\$12.04)
Assets (mil)	\$7.93
Liability (mil)	\$0.61
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Beckstead & Watts LLP expressed doubts on the ability of Ecotality, Inc. to continue as a going concern due to its limited operations and the fact that the Company has not commenced planned principal operations.

Intellectual Property: The Company has filed three provisional patent applications relating to the electric power cell (EPC) technology. The provisional patent applications are directed to EPC fueled by magnesium with a recycling system for replenishing the magnesium and electrolyte supply used for power generation, as well as a power cell fueled by hydrogen with a recycling system for replenishing the metal supply used for hydrogen generation. The Company entered into a License Agreement with California Institute of Technology, whereby it acquired certain exclusive licensed patent and/or patent applications rights and improvement patent rights related to research performed under the JPL Task Plan No. 82-10777. CalTech has granted the Company exclusive worldwide license, with the right to grant and authorize sublicenses, to make, have made, import, use, sell, and offer for sale any products, devices, systems, articles of manufacture, and compositions of matter, or processes or services that are covered by the patented CalTech Rights. [SEC Filing 10-KSB/A 04-17-07]

Description: The Company develops and commercializes electric power cell technology.

Officers: Jonathan R. Read (Pres., CEO & Dir.); Harold W. Sciotto (Sec., Treas. & Dir.); Barry S. Baer (CFO); Jerry Y.S. Lin, PhD. (Dir.)

Auditor: Beckstead & Watts LLP

Securities: Common Stock-Symbol ETLY.OB; OTC BB;
106,999,906 common shares outstanding as of April 12, 2006.

[Return to top](#)

**Prospector
Profile
07.0873**

Einstein Noah Restaurant Group, Inc.

1687 Cole Boulevard
Golden, CO 80401
(303) 568-8000

NAICS		722110
Description		Restaurants
Employees		300
Revenue	(mil)	\$389.96
Income	(mil)	(\$6.87)
Assets	(mil)	\$133.15
Liability	(mil)	\$265.39
(for the year ended 1/2/2007)		

Category: Loss/Deficit

Event: Einstein Noah Restaurant Group Inc., fka New World Restaurant Group, Inc., reported total assets of \$133.2 million, total liabilities of \$265.4 million, and total stockholders' deficit of \$132.2 million as of April 3, 2007. The Company had a negative working capital with total current assets of \$24.9 million and total current liabilities of \$32.9 million.

Intellectual Property: The tradenames, corporate names, trademarks and logos of Einstein Bros, Einstein Bros Bagels, Manhattan Bagels, Noah's New York Bagels, Chesapeake Bagels and New World Coffee are among the Company's valuable Marks. [Company Website]

Description: The Company owns, operates, franchises, and licenses bagel specialty restaurants in the United States.

Officers: Paul J.B. Murphy III (CEO & Dir.); Daniel J. Dominguez (COO); Richard P. Dutkiewicz (CFO); Jill B.W. Sisson (Sec. & Gen. Counsel); Michael W. Arthur (Dir.); James W. Hood (Dir.); E. Nelson Heumann (Dir.); Frank C. Meyer (Dir.); Leonard Tannenbaum (Dir.); S. Garrett Stonehouse, Jr. (Dir.)

Auditor: Grant Thornton LLP

Securities: Common Stock-Symbol NWRG.PK; Other OTC; 10,612,227 common shares outstanding as of February 28, 2007.

[Return to top](#)

**Prospector
Profile
07.0874**

Enzon Pharmaceuticals, Inc.

685 Route 202/206
Bridgewater, NJ 08807
(908) 541-8600

NAICS		325414
Description		Pharmaceuticals Mfg.
Employees		359
Revenue	(mil)	\$185.65
Income	(mil)	\$21.31
Assets	(mil)	\$403.83
Liability	(mil)	\$460.27
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: Enzon Pharmaceuticals, Inc., posted a \$1,853,000 net loss on \$41,488,000 of revenues for the quarter ended March 31, 2007, as compared with \$21,708,000 of net income on \$44,729,000 of revenues for the same quarter last year. At March 31, 2007, the Company's balance sheet showed \$368,809,000 in total assets and \$424,291,000 in total liabilities, resulting in a \$55,482,000 stockholders' deficit.

Intellectual Property: The Company has an extensive portfolio of issued U.S. patents and patent applications, many of which have foreign counterparts. Under several license agreements, the Company has access to large portions of Micromet's patent estates, as well as a small number of individually licensed patents. Of the Company's patents, 7 relate to PEG-INTRON, 17 relate to Abelcet, and 3 relate to DepoCyt. The patent covering its original PEG technology, which was licensed from Research Corporation Technologies, Inc., contained broad claims covering the attachment of PEG to polypeptides. However, this U.S. patent and its corresponding foreign patents have expired. In the field of SCA proteins, the Company has several U.S. and foreign patents and pending patent applications, including a patent granted in August 1990 covering the genes needed to encode SCA proteins. Through the acquisition of Abelcet, the Company acquired several U.S., Canadian, and Japanese patents claiming the use and manufacture of Abelcet. [SEC Filing 10-K 03-02-07]

Description: The Company develops, manufactures, and commercializes pharmaceutical products for the treatment of cancer and various life-threatening diseases in the U.S. and Canada.

Officers: Jeffrey H. Buchalter (Chair); Craig A. Tooman (EVP & CFO); Paul Davit (EVP); Ralph Del Campo (EVP); Ivan Horak (EVP & Chief Scientific Officer); Goran Ando (Dir.); Rolf A. Classon (Dir.); Robert LeBuhn (Dir.); Victor P. Micati (Dir.); Phillip M. Renfro (Dir.); Robert C. Salisbury (Dir.)

Auditor: KPMG LLP

Securities: Common Stock Symbol ENZN; NasdaqGM;
44,061,961 common shares outstanding as of May 2, 2007.

[Return to top](#)

**Prospector
Profile
07.0875**

Glowpoint, Inc.

225 Long Avenue
Hillside, NJ 07205
(973) 282-2000

NAICS	561499
Description	Videoconferencing
Employees	59
Revenue (mil)	\$19.51
Income (mil)	(\$10.79)
Assets (mil)	\$8.39
Liability (mil)	\$19.98
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Amper, Politziner & Mattia PC expressed substantial doubt about Glowpoint, Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the year ended Dec. 31, 2006. The auditing firm pointed to the Company's working capital deficiency and recurring net losses. Amper Politziner noted that the Company is in the process of seeking additional capital and that it has not yet secured sufficient capital to fund its operations.

Intellectual Property: The development of the Company's network architecture and video applications resulted in a significant amount of intellectual property - from real-time rating and billing for video calls to video call center applications for customer support. In 2007, the Company received its first patent and a number of others have been filed and are in various stages of the patent process. This patented and patent-pending proprietary technology provides an important barrier for competitive offerings of similar telephony-like managed video services. The Company was recently awarded U.S. Patent No. 7,200,213 B2 for its live video operator assistance feature. The Company has substantial intellectual property with regard to two-way video communications. [SEC Filing 10-K 06-06-07]

Description: The Company provides IP-based video communications services worldwide. It operates a video communications service network that spans four continents.

Officers: Michael Brandofino (Pres., CEO & Dir.); Edwin F. Heinen (EVP & CFO); Joseph Laezza (COO); David W. Robinson (EVP & Gen. Counsel); Aziz Ahmad (Dir.); Bami Bastani (Dir.); Dean Hiltzik (Dir.); James S. Lusk (Dir.); Richard Reiss (Dir.); Peter Rust (Dir.)

Auditor: Amper, Politziner & Mattia PC

Securities: Common Stock-Symbol GLOW.PK; Other OTC; 47,209,673 common shares outstanding as of May 31, 2007.

[Return to top](#)

**Prospector
Profile
07.0876**

GoFish Corporation

500 3rd Street, Suite 260
San Francisco, CA 94107
(415) 738-8705

NAICS	516110
Description	Internet Sites
Employees	22
Revenue (mil)	\$0.03
Income (mil)	(\$5.31)
Assets (mil)	\$5.50
Liability (mil)	\$0.95
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Rowbotham & Company LLP raised substantial doubt about the ability of GoFish Corporation to continue as a going concern due to its recurring net loss since inception and liquidity problems.

Intellectual Property: The Company has developed proprietary algorithmic filters to manage and screen content on its website. It also has developed proprietary search algorithms to assist people in finding video content more efficiently on its website. The Company has filed for trademark protection for the name "GOFISH" with the United States Patent and Trademark Office. [SEC Filing 10-KSB 04-17-07]

Description: The Company operates in the online video marketplace in the United States.

Officers: Michael Downing (CEO & Dir.); Tabreez Verjee (Pres. & Dir.); Greg Schroeder (Chief Technology Officer); Lennox L. Vernon (Chief Accounting Officer); Peter Guber (Dir.); Riaz Valani (Dir.)

Auditor: Rowbotham & Company LLP

Securities: Common Stock-Symbol GOFH.OB; OTC BB;
24,130,285 common shares outstanding as of April 12, 2007.

[Return to top](#)

**Prospector
Profile
07.0877**

Hendrx Corporation

2610-1066 West Hastings Street
Vancouver, British Columbia, Canada V6E 3X2
1-888-436-3791

NAICS		333319
Description		Purification Equipment Mfg.
Employees		197
Revenue	(mil)	\$2.25
Income	(mil)	(\$2.97)
Assets	(mil)	\$42.80
Liability	(mil)	\$4.81
(for the year ended 12/31/2006)		

Category: Audit Concerns

Event: Chisholm, Bierwolf & Nilson LLC expressed substantial doubt about Hendrx Corp.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the year ended Dec. 31, 2006. The auditing firm pointed to the Company's recurring losses from operations and working capital deficiency.

Intellectual Property: Hendrx owns two patents for atmospheric water generation in China under patent number P20030483 and utilizes four patents under sub-licenses registered in the United States under patent numbers 5,106,512; 5,149,466; 5,203,989 and 5,366,705. Further, additional PCT patents have been filed and are pending. [SEC Filing 10-KSB 04-03-07]

Description: The Company is engaged in the research and development, manufacture, marketing and world wide distribution of water generation, filtration, ionization, desalinization, and purification devices.

Officers: George Solymar (CEO & Dir.); Cherry Cai (CFO); Nadir Walji (Dir.)

Auditor: Chisholm, Bierwolf & Nilson LLC

Securities: Common Stock-Symbol HDRX.OB; OTC BB;
37,238,067 common shares outstanding as of March 30, 2007.

[Return to top](#)

**Prospector
Profile
07.0878**

ICP Solar Technologies, Inc.

7075 Place Robert-Joncas
Montreal, Quebec, Canada H4M 2Z2
(514) 270-5770

NAICS		334413
Description		Solar Cells Mfg.
Employees		46
Revenue	(mil)	\$7.60
Income	(mil)	(\$2.63)
Assets	(mil)	\$6.10
Liability	(mil)	\$5.03
(for the year ended 1/31/2007)		

Category: Audit Concerns

Event: RSM Richter LLP expressed substantial doubt on the ability of ICP Solar Technologies, Inc. to continue as a going concern after auditing its financial statements. The Company has reported an accumulated deficit of \$4,617,501 as of January 31, 2007. The auditor believes that additional capital and/or borrowings will be necessary in order for the Company to continue in existence and attain profitable operations.

Intellectual Property: The Company relies on trade secrets, common law trademark rights and trademark registrations and intends to protect intellectual property through non-disclosure agreements, license agreements and appropriate restrictions and controls on the distribution of information. At present, the Company has registered 49 trademarks in the U.S., U.K. and Canada. In addition, the Company has also filed 24 patent applications in the U.S., U.K. and Canada. [SEC Filing 10-KSB 05-01-07]

Description: The Company manufactures, markets, and sells solar panel based products to the consumer goods, Original Equipment Manufacturers and integrated building materials markets through distribution channels in over 100 countries.

Officers: Sass Peress (Chair, Pres. & CEO); Leon Assayag (CFO); Joel Cohen (Sec., Treas. & Dir.); David Dangoor (Dir.); Paul Maycock (Dir.); David McDowell (Dir.)

Auditor: RSM Richter LLP

Securities: Common Stock-Symbol ICPR.OB; OTC BB;
29,000,000 common shares outstanding as of May 1, 2007.

[Return to top](#)

**Prospector
Profile
07.0879**

Imcor Pharmaceutical Company

4660 La Jolla Drive, Suite 500
San Diego, CA 92122
(858) 546-2955

NAICS	339100
Description	Medical Equipment Mfg.
Revenue (mil)	\$1.20
Income (mil)	(\$0.35)
Assets (mil)	\$1.34
Liability (mil)	\$4.60
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Squar, Milner, Peterson, Miranda & Williamson LLP expressed substantial doubt about the ability of Imcor Pharmaceutical Company to continue as a going concern after auditing its financial statements. The Company has reported accumulated losses since inception of \$91,239,032, and as of December 31, 2006, has a working capital deficit of approximately \$3,263,305.

Intellectual Property: The Company has 20 issued U.S. patents and 4 pending U.S. patent applications, which are directed to the composition, manufacture, and use of novel stabilized microbubble compositions used in ultrasound or harmonic ultrasound imaging. Foreign applications directed to the same subject matter are also granted or pending. It also has issued U.S. patents covering the use of various contrast agents, including Imagent, in harmonic imaging. The Company protects proprietary products, processes and other information by relying on trade secret laws and non-disclosure and confidentiality agreements. "IMCOR" is a trademark and Imagent® is a registered trademark of the Company. [SEC Filing 10-KSB 04-17-07]

Description: The Company owns Imagent, an ultrasound imaging contrast agent for use in patients with suboptimal echocardiograms.

Officers: Brian M. Gallagher, Ph.D. (Chair); Taffy J. Williams, Ph.D. (Dir.); Robert A. Ashley (Dir.); Richard T. Dean, Ph.D. (Dir.); Darlene M. Deptula-Hicks, M.B.A. (Dir.); Jonathan J. Fleming (Dir.); Alan D. Watson, Ph.D., M.B.A. (Dir.)

Auditor: Squar, Milner, Peterson, Miranda & Williamson LLP

Securities: Common Stock-Symbol ICRP.PK; Other OTC;
6,962,456 common shares outstanding as of March 31, 2007.

[Return to top](#)

**Prospector
Profile
07.0880**

Impact Medical Solutions, Inc.

17011 Beach Blvd., Suite 900
Huntington Beach, CA 92647
(714) 841-2670

NAICS	511210
Description	Software Publishers
Employees	4
Revenue (mil)	\$0.00
Income (mil)	(\$2.08)
Assets (mil)	\$0.46
Liability (mil)	\$0.61
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Farber Hass Hurley & McEwen LLP expressed substantial doubt on the ability of Impact Medical Solutions, Inc. to continue as a going concern after auditing the Company's financial statements. During the years ended December 31, 2006 and 2005, the Company incurred a net loss of \$2,077,147 and \$1,496,992 respectively. The auditor also notes that the Company has not earned any revenue since inception.

Intellectual Property: The Company's technology is protected by Patent No. 6,280,395 for Muscle Pattern Recognition, which was approved in August 2001. Its Muscle Pattern Recognition patent protects the method for determining muscle dysfunction of a subject; the system for determining muscle dysfunction of a subject; the computer readable medium having stored instructions for analyzing the muscle dysfunction of a subject; a muscle dysfunction evaluation network for determining muscle dysfunction of subjects; and a muscle dysfunction report. [SEC Filing 10-KSB 04-17-07]

Description: The Company is engaged in the healthcare information-technology market. It provides valid and reliable clinical tools for the assessment of human physiology and body function.

Officers: Donald Paterson (Chair); Wayne D. Cockburn (Pres., CEO & Dir.); George Angelidis (Dir.); Stephen Schectman (Dir.)

Auditor: Farber Hass Hurley & McEwen LLP

Securities: Common Stock-Symbol IMSU.OB; OTC BB; 15,853,465 common shares outstanding as of April 16, 2007.

[Return to top](#)

**Prospector
Profile
07.0881**

InforMedix Holdings, Inc.

Georgetowne Park
5880 Hubbard Drive
(301) 984-1566

NAICS	334510
Description	Patient Monitoring Equipment
Employees	7
Revenue (mil)	\$0.10
Income (mil)	(\$6.75)
Assets (mil)	\$0.90
Liability (mil)	\$2.68
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Bagell Josephs Levine & Company LLC raised doubts on the ability of InforMedix Holdings, Inc. to continue as a going concern after auditing its financial statements. The auditor notes that the Company incurred net operating losses for the years ended December 31, 2006, and 2005. The Company emerged from the development stage in early 2004, and there is no guarantee whether the Company will be able to generate enough revenue and/or raise capital to support current operations and expand sales.

Intellectual Property: InforMedix has developed, patented and integrated a portable interactive patient monitoring “smart pillbox” appliance, software and networked two-way communications system to enable insurance companies, disease management organizations, pharmaceutical firms, medical researchers and physicians to efficiently monitor and manage patients’ adherence to their medications and care plans. The Med-eMonitor™ System leverages InforMedix’s rich pioneering patent portfolio of 15 issued and 14 pending patents. [SEC Filing 10-KSB 05-04-07]

Description: The Company provides a portable patient monitoring device, software, and networked communications system that enables insurance companies, disease management organizations, pharmaceutical firms, medical researchers, and physicians to monitor and manage patient's medication adherence and clinical response.

Officers: Bruce A. Kehr, MD (Chair & CEO); Harry M. Stokes (SVP, CFO & Sec.); Davidson R. Dulin (SVP); Michael P. Gavin (VP); Rhonda B. Friedman (Dir.); Philip J. Gross, CPA (Dir.); Harris Kaplan (Dir.); Bruce S. Morra, PhD, MBA (Dir.); David Nash, MD, MBA (Dir.)

Auditor: Bagell Josephs Levine & Company LLC

Securities: Common Stock-Symbol IFMX.OB; OTC BB;
92,050,624 common shares outstanding as of April 25, 2007.

[Return to top](#)

**Prospector
Profile
07.0882**

Liberty Diversified Holdings, Inc.

2100 W. Orangewood, Ste. 220
Orange, CA 92868
(949) 376-4846

NAICS	551114
Description	Management of Companies
Employees	3
Revenue (mil)	\$3.64
Income (mil)	(\$1.51)
Assets (mil)	\$0.36
Liability (mil)	\$0.52
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Kabani & Company, LLC notes that Liberty Diversified Holdings, Inc. has had recurring operating losses, has an accumulated deficit, has a negative working capital, and was dependent upon additional financing to continue operations. These factors indicate that the Company may be unable to continue in existence.

Intellectual Property: The Company owns the StickyBar Toolbar™ technology, plus all source codes, all current and future patents and patents pending, and exclusive licensing rights to the StickyBar product and technology. In addition, SofCast has also transferred five custom toolbars ready for deployment including the Hotel Collection, radio, talking, Real Estate and TV toolbars. Its Serotonin Solutions, Inc. subsidiary holds exclusive worldwide marketing licenses for the patented Serotrim® Weight Loss Drink and the Serotonin Weight Loss Diet, including license to use the Serotrim® trademark. [SEC Filing 10-KSB 04-17-07]

Description: The Company focuses in part on the acquisition and development of viable subsidiaries.

Officers: Ronald C. Touchard (Co-Chair & CEO); Wayne K. Bailey (CFO & Sec.)

Auditor: Kabani & Company, LLC

Securities: Common Stock-Symbol LDHIE.OB; OTC BB;
629,499,213 common shares outstanding as of April 17, 2007.

[Return to top](#)

**Prospector
Profile
07.0883**

LipidViro Tech, Inc.

1338 S Foothill Drive, Suite 126
Salt Lake City, UT 84108
(801) 583-9900

NAICS 541710
Description Biotechnology

Revenue	(mil)	\$0.00
Income	(mil)	(\$3.29)
Assets	(mil)	\$0.37
Liability	(mil)	\$0.73

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Pritchett Siler & Hardy PC expressed doubts on the ability of LipidViro Tech, Inc. to continue as a going concern due to its incurred losses since inception. In addition, the auditor points out that the Company had not yet generated any revenues, and had current liabilities in excess of current assets.

Intellectual Property: The Company has applied for patent protection covering its d-OSAB Therapy technology, a treatment targeting cardiovascular disease and stroke. In addition to patents, the Company relies on trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain its competitive position. [SEC Filing 10-KSB 04-17-07]

Description: The Company engages in the research and development of d-OSAB Therapy, a treatment targeting cardiovascular disease and stroke; and PathPure, a purification process for production of pathogen-free biologics.

Officers: Steven Keyser (Chair); Kenneth P. Hamik (Pres. & Dir.); Kristy Hamik (COO & Dir.); Linda Sharkus (Dir.)

Auditor: Pritchett Siler & Hardy PC

Securities: Common Stock-Symbol LPVT.OB; OTC BB;
17,805,042 common shares outstanding as of April 17, 2007.

[Return to top](#)

**Prospector
Profile
07.0884**

Medlink International, Inc.

11 Oval Drive, Suite 200 B
Islandia, NY 11749
(631) 342-8800

NAICS	511210
Description	Software Publishers
Employees	11
Revenue (mil)	\$0.01
Income (mil)	(\$1.59)
Assets (mil)	\$0.06
Liability (mil)	\$0.45
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Jewett Schwartz Wolfe & Associates raised substantial doubt about the ability of Medlink International, Inc. to continue as a going concern after auditing its financial statements. The auditor noted that the Company has operating and liquidity concerns, and has incurred an accumulated deficit of approximately \$10,824,641 through the period ended December 31, 2006.

Intellectual Property: The Company has trademarked the name MedLink VPN, MedLink EHR, and MedLink TV. [SEC Filing 10-KSB 04-17-07]

Description: The Company, through its subsidiaries, engages in the sale, implementation, and support of software solutions and hardware for healthcare providers in the United States.

Officers: Ray Vuono (Chair, Pres. & CEO); Konrad Kim (Chief Technology Officer & Dir.); James Rose (EVP & CFO); James Decker (EVP); Dr. Michael Carvo (Dir.)

Auditor: Jewett Schwartz Wolfe & Associates

Securities: Common Stock-Symbol MLKNA.OB; OTC BB; 16,616,784 common shares outstanding as of March 31, 2007.

[Return to top](#)

**Prospector
Profile
07.0885**

Nanobac Pharmaceuticals, Incorporated

4730 North Habana Avenue, Suite 205
Tampa, FL 33614
(813) 264-2241

NAICS	541710
Description	Biotechnology
Employees	3
Revenue (mil)	\$0.23
Income (mil)	(\$4.97)
Assets (mil)	\$7.82
Liability (mil)	\$9.14
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Aidman, Piser & Company, P.A. notes that Nanobac Pharmaceuticals, Inc. has suffered recurring losses from operations, has working capital and net capital deficiencies and is dependent upon continued financing from stockholders and/or outside investors, all of which raises doubts about its ability to continue as a going concern.

Intellectual Property: The Company has a family of patents encompassing the detection and eradication of nanobacteria. The Company's registered patents include two U.S. and one PCT patents for Method for the culture and detection of nanobacteria also known as calcifying nanoparticles and Methods for the eradication of Nanobacteria from articles and animals. It also has six U.S. and five PCT patent applications pending. [SEC Filing 10-KSB 05-04-07]

Description: The Company engages in the research and development of therapeutic and diagnostic technologies related to nanobacterium sanguineum.

Officers: John Stanton (Chair, CEO & CFO); Alex Edwards (Dir.); Dr. Benedict Maniscalco (Dir.); Dr. Stephen Rechtschaffen (Dir.)

Auditor: Aidman, Piser & Company, P.A.

Securities: Common Stock-Symbol NNBP.OB; OTC BB;
247,476,426 common shares outstanding as of May 1, 2007.

[Return to top](#)

**Prospector
Profile
07.0886**

Naturally Advanced Technologies, Inc.

1307 Venables Street
Vancouver, British Columbia, Canada V5L 2G1
(604) 255-5005

NAICS		313111
Description		Yarn Mills
Employees		16
Revenue	(mil)	\$1.27
Income	(mil)	(\$1.37)
Assets	(mil)	\$1.20
Liability	(mil)	\$0.93
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: Naturally Advanced Technologies Inc. reported a net loss of \$134,818 on sales of \$616,061 for the first quarter ended March 31, 2007, compared with a net loss of \$324,824 on sales of \$285,194 for the same quarter last year. At March 31, 2007, the Company's balance sheet showed \$1,448,074 in total assets and \$1,123,729 in total liabilities, and \$324,345 in total stockholders' equity.

Intellectual Property: During 2004, the Company entered into a collaboration with Canada's National Research Council to commercialize a patentable process for extracting and cleaning hemp fiber and converting it into a proprietary fiber called "CRAILAR". Management believes that consumer awareness, acceptance and demand for the hemp/cotton product is continuing to grow. The Company has obtained trademark protection for the name "CRAILAR" within Canada and the United States. It also owns the web sites www.naturallyadvanced.com, www.hemptown.com, www.hemptownclothing.ca, www.crailar.com and www.htnaturals.com. [SEC Filing 10-KSB 04-02-07]

Description: The Company is a leading provider of sustainable, environmentally-friendly fibers and fabrics.

Officers: Jerry Kroll (Chair); Kenneth C. Barker (CEO & Dir.); Jason Finnis (Pres., COO & Dir.); Larisa Harrison (Chief Administration Officer, Sec., Treas. & Dir.); Guy Prevost (CFO & Dir.); Robert Edmunds (Dir.); Peter Moore (Dir.); Miljenko Horvat (Dir.)

Auditor: Dale Matheson Carr-Hilton Labonte LLP

Securities: Common Stock-Symbol NADVF.OB; OTC BB;
24,178,726 common shares outstanding as of March 23, 2007.

[Return to top](#)

**Prospector
Profile
07.0887**

Nayna Networks, Inc.

4699 Old Ironsides Drive, Suite 420
Santa Clara, CA 95054
(408) 956-8000

NAICS		334200
Description		Communications Equipment Mfg.
Employees		31
Revenue	(mil)	\$0.48
Income	(mil)	(\$20.00)
Assets	(mil)	\$3.73
Liability	(mil)	\$27.61
(for the year ended 12/31/2006)		

Category: Audit Concerns

Event: Nareshkumar H. Arora raised substantial doubt about the ability of Nayna Networks, Inc. to continue as a going concern due to its recurring losses from operations.

Intellectual Property: The Company has obtained 17 patents in the area of networking and optical networking and filed several other patent applications. Its trade secret intellectual property includes valuable software/firmware combinations that ensure billable quality traffic enforcement known in the industry as quality of service. Quality of service software provides extra revenue opportunities for both its products and synergistic services. Quality of service is of vital importance in the Video on Demand market segment where consumers pay to view a movie or special sporting event. Quality of service is also of critical importance to the leased line market segment where, for example, mission critical corporate PBX traffic is carried to the central office. [SEC Filing 10-KSB/A 05-01-07]

Description: The Company engages in the design, development, and marketing of broadband access networking solutions for the secure communications market worldwide.

Officers: Naveen S. Bisht (Pres., CEO & Dir.); Gautam Chanda (SVP); Hari Harani (VP); Dr. Raj Jain (Chief Technology Officer); Thomas Richtarich (Interim CFO)

Auditor: Nareshkumar H. Arora

Securities: Common Stock-Symbol NAYN.OB; OTC BB;
65,829,463 common shares outstanding as of April 17, 2007.

[Return to top](#)

**Prospector
Profile
07.0888**

NPS Pharmaceuticals, Inc.

383 Colorow Drive
Salt Lake City, UT 84108
(801) 583-4939

NAICS		325412
Description		Pharmaceuticals Mfg.
Employees		196
Revenue	(mil)	\$48.50
Income	(mil)	\$112.67
Assets	(mil)	\$224.74
Liability	(mil)	\$417.98
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: NPS Pharmaceuticals, Inc., posted a \$21,144,000 net loss on \$9,991,000 of total revenues for the quarter ended March 31, 2007, as compared with a \$38,329,000 net loss on \$6,083,000 of revenues for the same quarter last year. At March 31, 2007, the Company's balance sheet showed \$180,475,000 in total assets and \$393,062,000 in total liabilities, resulting in a \$212,587,000 stockholders' deficit.

Intellectual Property: The Company holds patents directed to potential therapeutic products such as new chemical entities, pharmaceutical compositions and methods of treating diseases. It holds patents directed also to nucleic acid and amino acid sequences of novel cellular receptors and methods of screening for compounds active at such cellular receptors. The Company has been issued approximately 196 patents in the U.S. and has been granted approximately 890 patents in other countries. Ten issued U.S. patents cover technology related to parathyroid hormone. Seven issued U.S. patents cover technology related to calcilytic compounds. Fifteen issued U.S. patents cover calcimimetics and calcium receptor technology. Thirteen issued U.S. patents cover technology related to teduglutide and GLP-2, certain of which are licensed from 1149336 Ontario Inc. Eleven issued U.S. patents cover technology related to metabotropic glutamate receptors. Thirteen issued U.S. patents cover technology related to glycine reuptake inhibitors. [SEC Filing 10-K 03-14-07]

Description: The Company discovers, develops, and commercializes therapeutic small molecule drugs and recombinant proteins.

Officers: N. Anthony Coles (Pres. & CEO); Val R. Antczak (SVP, Gen. Counsel & Sec.); Juergen Lasowski (SVP); Gregory Torre (SVP); Gerard J. Michel (VP & CFO); Glenn R. Melrose (VP); Alan L. Mueller (VP); Francois Nader (Chief Medical & Commercial Officer)

Auditor: KPMG LLP

Securities: Common Stock Symbol NPSP; NasdaqGM;
46,340,685 common shares outstanding as of May 8, 2007.
3.0% convertible notes due June 15, 2008; 8.0% secured notes due March 30, 2017.

[Return to top](#)

**Prospector
Profile
07.0889**

Orthometrix, Inc.

106 Corp. Park Dr., Ste. 106
White Plains, NY 10604
(914) 694-2285

NAICS		339100
Description		Medical Equipment Mfg.
Employees		9
Revenue	(mil)	\$2.36
Income	(mil)	(\$1.98)
Assets	(mil)	\$1.17
Liability	(mil)	\$3.47
(for the year ended 12/31/2006)		

Category: Audit Concerns

Event: Radin Glass & Co., LLP expressed substantial doubt about Orthometrix, Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the year ended Dec. 31, 2006. The auditing firm pointed to the Company's recurring operating losses and net capital deficit. The Company posted a \$1,980,314 net loss on \$2,362,427 of revenues for the year ended Dec. 31, 2006. The Company's balance sheet also showed \$2,285,755 in stockholders' deficit and strained liquidity with \$1,081,467 in total current assets and \$2,828,428 in total current liabilities.

Intellectual Property: The Company relies primarily on know-how, trade secrets and trademarks to protect those intellectual property rights. Other than the application by the licensor of the Galileo™ products, it has not sought patent protection for such products. The VibraFlex® product is a registered trademark held by the Company. [SEC Filing 10-KSB 06-06-07]

Description: The Company markets, sells and services several musculoskeletal product lines used in pharmaceutical research, diagnosis and monitoring of bone and muscle disorders, sports medicine, rehabilitative medicine, physical therapy and pain management.

Officers: Reynald G. Bonmati (Chair, Pres. & CEO); Neil H. Koenig (CFO); William Orr (Dir.); Michael W. Huber (Dir.); Andre-Jacques Neusy (Dir.); Albert S. Waxman (Dir.)

Auditor: Radin, Glass & Co., LLP

Securities: Common Stock-Symbol OMRX.OB; OTC BB;
45,178,618 common shares outstanding as of May 7, 2007.

[Return to top](#)

**Prospector
Profile
07.0890**

Oxford Media, Inc.

One Technology Drive, Building H
Irvine, CA 92618
(949) 341-0050

NAICS	515210
Description	Entertainment Programming
Employees	168
Revenue (mil)	\$6.49
Income (mil)	(\$28.50)
Assets (mil)	\$14.56
Liability (mil)	\$30.36
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: McKennon Wilson & Morgan LLP notes that Oxford Media, Inc. has incurred losses from operations and negative cash flows from operating activities during the year ended December 31, 2006 and 2005. The Company also had a working capital deficiency of \$5,287,369 at December 31, 2006. These factors raise substantial doubt about the Company's ability to continue as a going concern.

Intellectual Property: Effective December 31, 2005, the Company consummated a transaction to acquire PDHK Services, Inc., a privately held company specializing in content delivery software over wireless and IP networks. This acquisition gave them the technology license formally held by PDHK used in the delivery of content delivery over future Private Broadband Networks. The Company also acquired eight patents as result of its acquisition of SVI Hotel Corporation. [SEC 10-KSB 04-17-07]

Description: The Company provides technology, content, and support services for in-room entertainment.

Officers: David Parker (Vice Chair); Lewis Jaffe (Pres., CEO & Dir.); Elizabeth Salmon (COO); David Malm (Dir.); Brian Weiss (Interim CFO)

Auditor: McKennon Wilson & Morgan LLP

Securities: Common Stock-Symbol OXMI.OB; OTC BB;
38,951,807 common shares outstanding as of March 31, 2007.

[Return to top](#)

**Prospector
Profile
07.0891**

Playtex Products, Inc.

300 Nyala Farms Road
Westport, CT 06880
(203) 341-4000

NAICS		325600
Description		Toiletries Mfg.
Employees		1,250
Revenue	(mil)	\$636.15
Income	(mil)	\$30.20
Assets	(mil)	\$927.63
Liability	(mil)	\$785.36
(for the year ended 12/31/2006)		

Category: Low Rating

Event: Moody's Investors Service affirmed its Caa1, LGD5, 83% rating on Playtex Products, Inc.'s \$289 million 9.375% senior subordinated notes due 2011. The rating outlook is positive. Moody's said that the rating action is a result of the higher proportion of secured debt in the Company's capital structure to accommodate its recently closed acquisition of Hawaiian Tropic for \$108 million.

Intellectual Property: The Company owns royalty-free licenses in perpetuity to the Playtex and Living trademarks in the United States, Canada and many foreign jurisdictions related to certain feminine hygiene, baby care, gloves and other products. In addition, the Company owns rights to a number of United States, Canadian and foreign trademarks that are important to its business, including: Banana Boat®, Beyond®, Binky®, Celebrate The Sun™, Coolster™, Create My Own™, Diaper Genie®, Drop-Ins®, Eat and Discover™, Embrace™, First Sipster®, Gentle Glide®, Get On The Boat®, HandSaver®, Insulator®, Insulator Sport®, NaturaLatch®, Natural Shape®, Nursing Necessities™, Ortho-Pro™, QuickStraw®, Quik Blok®, Sipster®, Sport™, UltraMist™, VentAire®, and Wet Ones®. It also owns various United States, Canadian and foreign patents. The patent rights include plastic and cardboard applicators for tampons, baby bottles and nipples, disposable liners and plastic holders for the nurser systems, children's drinking cups, pacifiers, sunscreen formulation, diaper disposal systems, and breast pump products. [SEC Filing 10-K 03-13-07]

Description: The Company manufactures and markets a portfolio of branded consumer and personal products.

Officers: Neil P. DeFeo (Chair, Pres. & CEO); Kris J. Kelley (EVP & CFO); Perry R. Beadon (SVP); Gary S. Cohen (SVP); James S. Cook (SVP); Thomas M. Schultz (SVP); Gretchen R. Crist (VP); Blair P. Hawley (VP); Paul E. Yestrumkas (VP, Gen. Counsel & Sec.)

Auditor: KPMG LLP

Securities: Common Stock Symbol PYX; NYSE;
63,461,736 common shares outstanding as of April 30, 2007.

[Return to top](#)

**Prospector
Profile
07.0892**

Premiere Publishing Group, Inc.

386 Park Avenue South, 16th Floor
New York, NY 10016
(212) 481-1005

NAICS	511120
Description	Magazine Publisher
Employees	16
Revenue (mil)	\$5.41
Income (mil)	(\$1.81)
Assets (mil)	\$1.45
Liability (mil)	\$2.50
(for the year ended 12/31/2006)	

Category: Loss/Deficit

Event: Premiere Publishing Group, Inc. reported a net loss of \$528,766 on revenues of \$771,557 for the first quarter ended March 31, 2007, compared with a net loss of \$90,886 on revenues of \$826,984 for the same period ended March 31, 2006. The Company's balance sheet showed \$1,523,623 in total assets and \$2,934,233 in total liabilities, resulting in a \$1,410,619 total stockholders' deficit. It also showed strained liquidity with \$1,296,963 in total current assets available to pay \$2,646,372 in total current liabilities at March 31, 2007.

Intellectual Property: The Company's wholly-owned subsidiary Sobe Life, LLC entered into a license agreement with Donald J. Trump on May 28, 2004 that grants them an exclusive license to use the "Trump" trademark as the name of its magazine through August 30, 2009. [SEC Filing 10-KSB 04-02-07]

Description: The Company publishes the national quarterly magazine Trump Magazine, a glossy full-color magazine of approximately 112 pages that reflects the interests, business accomplishments and luxurious lifestyle of Donald Trump.

Officers: Michael Jacobson (Chair, Pres. & CEO)

Auditor: Gruber and Company LLC

Securities: Common Stock-Symbol PPLB.OB; OTC BB;
25,051,981 common shares outstanding as of December 31, 2006.

[Return to top](#)

**Prospector
Profile
07.0893**

Protein Polymer Technologies, Inc.

10655 Sorrento Valley Road
San Diego, CA 92121
(858) 558-6064

NAICS	541710
Description	Biotechnology
Employees	18
Revenue (mil)	\$0.60
Income (mil)	(\$7.88)
Assets (mil)	\$0.96
Liability (mil)	\$5.52
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Squar, Milner, Peterson, Miranda & Williamson LLP raised substantial doubt about the ability of Protein Polymer Technologies, Inc. to continue as a going concern after auditing its financial statements. The Company incurred a net loss of \$7,878,000 and had a working capital deficit of \$4,946,000 at December 31, 2006. The auditor points out that the Company's cash and cash equivalents of \$73,000 are insufficient to meet its anticipated capital requirements.

Intellectual Property: The Company is aggressively pursuing domestic and international patent protection for its technology, making claim to an extensive range of recombinantly prepared structural and functional proteins, the DNA encoding these proteins, methods for preparing this synthetic repetitive DNA, methods for the production and purification of protein polymers, end-use products incorporating such materials and methods for their use. The U.S. Patent and Trademark Office has issued 26 patents to the Company, with an additional 5 U.S. patent applications pending. The Company has been granted 5 U.S. patents that broadly cover the polymer compositions used in its product development efforts and/or the DNA encoding these polymers. It also has been granted a U.S. patent that covers the method of using polymers such as these silk/elastin copolymers for soft tissue augmentation. The Company has been granted 8 U.S. patents covering its tissue adhesive and sealant technology. It also has been granted 2 U.S. patents covering the methods used to construct the synthetic DNA encoding proteins having repetitive amino acid sequences. The Company has been granted and maintain 8 U.S. patents that are not currently central to its product development focus. [SEC Filing 10-KSB 05-04-07]

Description: The Company engages in the research, development, production, and clinical testing of bio-active devices to improve medical and surgical outcomes.

Officers: William N. Plamondon, III (Chair & CEO); Joseph Cappello, Ph.D. (VP, Chief Technical Officer & Dir.); Franco A. Ferrari, Ph.D. (VP); John E. Flowers (VP)

Auditor: Squar, Milner, Peterson, Miranda & Williamson LLP

Securities: Common Stock-Symbol PPTI.OB; OTC BB;
67,809,204 common shares outstanding as of March 30, 2007.

[Return to top](#)

**Prospector
Profile
07.0894**

Pure Vanilla Exchange, Inc.

805 Third Avenue, 15th Floor
New York, NY 10022
(212) 972-1600

NAICS	541511
Description	Custom Software Programming
Employees	1
Revenue (mil)	\$0.08
Income (mil)	(\$14.12)
Assets (mil)	\$2.39
Liability (mil)	\$9.98
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Imowitz Koenig & Co. LLP raised doubts on the ability of Pure Vanilla Exchange, Inc. to continue as a going concern after auditing its financial statements. For the years ended December 31, 2006 and 2005, the Company incurred net losses of approximately \$14,120,000 and \$3,329,000, respectively, and a total negative cash flow from operations of approximately \$6,747,000. The auditor states that the Company's continued existence is dependent upon several factors, including raising significant capital, the successful development of its online and stored value card services and the ability to achieve profitability from the sale of products and services.

Intellectual Property: The Company has filed two United States patent applications relating to its business processes. It intends to continue to rely on patent, trademark, service mark, copyright and trade secret laws, as applicable, and on restrictions on disclosure and transfer of title and other methods. [SEC Filing 10-KSB 04-17-07]

Description: The Company provides anonymous card/payment systems to tackle the issues of credit card fraud and identity theft.

Officers: Steven Yevoli (Chair & CEO); Paul Corvino (Pres.); Tucker Taylor (COO); John Cook (Controller & Sec.); George W. Benedict (Dir.); Thomas J. Fanning (Dir.); Jed Schutz (Dir.)

Auditor: Imowitz Koenig & Co., LLP

Securities: Common Stock-Symbol PVNX.OB; OTC BB;
70,826,542 common shares outstanding as of April 13, 2007.

[Return to top](#)

**Prospector
Profile
07.0895**

Sedona Corporation

1003 W 9th Avenue, Second Floor
King Of Prussia, PA 19406
(610) 337-8400

NAICS	511210
Description	Software Publishers
Employees	14
Revenue (mil)	\$1.42
Income (mil)	(\$2.37)
Assets (mil)	\$0.72
Liability (mil)	\$8.80
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: McGladrey & Pullen, LLP raised substantial doubt about the ability of Sedona Corporation to continue as a going concern after auditing the Company's financial statements. In addition to the net loss of \$2,252,000 in 2006, the Company incurred substantial losses from operations of approximately \$2,894,000 during the year ended December 31, 2005 and has negative working capital and shareholders' equity.

Intellectual Property: The Company has a service mark for a logo design, which was registered with the United States Patent and Trademark Office on July 23, 2002 (Registration No. 2598107), and a second service mark for the word mark "SEDONA" that was registered on March 24, 2003 (Registration No. 2700294). The Company also filed an application for federal registration of the word mark "INTARSIA®" on March 8, 2000 and was published for opposition on September 4, 2001. The Company has the exclusive right to use the "Intarsia®" trademark in connection with its services. [SEC Filing 10-KSB 04-17-07]

Description: The Company operates as a software application and services provider that develops and markets Web-based vertical customer/member relationship management (CRM/MRM) solutions to small and midsize businesses in the United States.

Officers: David R. Vey (Chair); Marco A. Emrich (Pres., CEO & Dir.); Anita M. Primo (VP, CFO & Sec.); Timothy A. Rimlinger (VP & Chief Technology Officer); David C. Bluestone (Dir.); Scott C. Edelman (Dir.); Victoria V. Looney (Dir.); Jack A. Pellicci (Dir.); Roger W. Scarce (Dir.)

Auditor: McGladrey & Pullen, LLP

Securities: Common Stock-Symbol SDNA.OB; OTC BB; 90,298,303 common shares outstanding as of April 11, 2007.

[Return to top](#)

**Prospector
Profile
07.0896**

Sipex Corporation

233 South Hillview Drive
Milpitas, CA 95035
(408) 934-7500

NAICS	334412
Description	Circuits Mfg.
Employees	285
Revenue (mil)	\$78.75
Income (mil)	(\$41.23)
Assets (mil)	\$59.55
Liability (mil)	\$67.67
(for the year ended 12/30/2006)	

Category: Loss/Deficit

Event: Sipex Corp. posted a \$6,290,000 net loss on \$16,859,000 of revenues for the quarter ended March 31, 2007, as compared with a \$13,799,000 net loss on \$17,854,000 of revenues for the quarter ended April 1, 2006. At March 31, 2007, the Company's balance sheet showed \$53,301,000 in total assets and \$65,704,000 in total liabilities, resulting in a \$12,403,000 stockholders' deficit.

Intellectual Property: The Company seeks to protect proprietary technology through patents and trade secret protection. Currently, the Company holds a number of patents and has additional United States patent applications pending. The Company also relies on trade secrets and confidential technological know-how in the conduct of its business. [SEC Filing 10-K 03-30-07]

Description: The Company makes more than 1,000 kinds of analog integrated circuits, power management circuits for handheld electronics, and power regulators used in industrial controls. It also makes photodetector chips and laser diode drivers used in optical storage systems.

Officers: Ralph Schmitt (CEO & Dir.); Clyde R. Wallin (SVP & CFO); Rick C. Hawron (SVP); Ed La, (SVP); Joel Camarda (SVP); Lee Cleveland (SVP)

Auditor: Deloitte & Touche LLP

Securities: Common Stock Symbol SIPX.PNK; Other OTC;
18,727,741 common shares outstanding as of May 7, 2007.
5.5% redeemable convertible senior notes due 2026.

[Return to top](#)

**Prospector
Profile
07.0897**

Skins, Inc.

45 West 21st Street, 2nd Floor
New York, NY 10010
(212) 561-5111

NAICS	316211
Description	Footwear Mfg.
Employees	5
Revenue (mil)	\$0.00
Income (mil)	(\$4.10)
Assets (mil)	\$2.04
Liability (mil)	\$0.30
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Mahoney Cohen & Company, CPA, P.C. notes that Skins, Inc. has no established source of revenues and has accumulated losses of \$4,785,298 since its commencement. Its ability to continue as a going concern is dependent upon achieving production or sale of goods, the ability of the Company to obtain the necessary financing to meet obligations and pay liabilities arising from normal business operations when they come due and upon profitable operations. The auditor states that these conditions raised substantial doubt that the Company will be able to continue as a going concern.

Intellectual Property: The Company has applied for a U.S. patent relating to its Modular Shoe System. The Company also filed international (PCT) Patent App. No. PCT/US04/33446 for the Modular Shoe System on October 7, 2004, for which it has filed national and regional entry applications in Canada, Australia, China (PRC), Japan, New Zealand, South Korea, the European Patent Office, the Russian Federation and Israel. On November 20, 2006, the U.S. patent and trademark office allowed and approved the patent application for a modular shoe system in the U.S. On February 6, 2007, the Company was issued patent number 7,171,768 for the Modular Shoe System. Two additional U.S. patent applications related to the issued patent are pending. [SEC Filing 10-KSB 04-17-07].

Description: The Company engages in the design, manufacture, and marketing of men's and women's footwear.

Officers: Michael J. Rosenthal (Chair); Mark Klein (Pres., CEO & Dir.); Antonio Pavan (EVP & COO); Stephen Hochberg (Dir.); Steve Reimer (Dir.); Frank Zambrelli (Dir.)

Auditor: Mahoney Cohen & Company, CPA, P.C.

Securities: Common Stock-Symbol SKNN.OB; OTC BB;
36,771,745 common shares outstanding as of April 13, 2007.

[Return to top](#)

**Prospector
Profile
07.0898**

Skylyft Media Networks, Inc.

100 East Verdugo Avenue
Burbank, California 91502
(818) 605-0957

NAICS		339950
Description		Sign Manufacturing
Employees		4
Revenue	(mil)	\$0.09
Income	(mil)	(\$0.40)
Assets	(mil)	\$1.42
Liability	(mil)	\$0.50
(for the year ended 12/31/2006)		

Category: Audit Concerns

Event: Drakeford & Drakeford, LLC expressed substantial doubt about the ability of Skylyft Media Networks, Inc. to continue as a going concern after auditing its financial statements. The auditor points out that the Company had no significant revenues and has incurred losses of \$1,040,390 for the period December 18, 2003 to December 31, 2006.

Intellectual Property: The Company's SkyBanr Mini-Lift system patent is pending in United States and Canada. It also has a Patent Co-operation Treaty application for the European Patent rights with a priority filing date as of November 9, 1999. [SEC Filing 10-KSB 04-17-07]

Description: The Company is organized into two operating divisions: Skylyft™ Manufacturing, which manufactures the SkyBanr Mini-Lift Hoist; and Skylyft™ Digital Imaging, which produces all of the printing medium.

Officers: Richard D. S. Yanke (Pres., CEO, Sec. & Dir.); Greg Guido (CFO); Damien A. Aranche (VP); Jim Ryan (VP); Larry Shamhart (Dir.)

Auditor: Drakeford & Drakeford, LLC

Securities: 25,432,495 common shares outstanding as of December 31, 2006.

Notes: There currently is no public market for its common stock.

[Return to top](#)

**Prospector
Profile
07.0899**

The Certo Group Corporation

201 Circle Drive North, Suite 112
Piscataway, NJ 08854
(732) 356-9555

NAICS	722110
Description	Restaurants
Employees	200
Revenue (mil)	\$10.03
Income (mil)	(\$2.87)
Assets (mil)	\$3.96
Liability (mil)	\$6.69
(for the year ended 12/31/2005)	

Category: Audit Concerns

Event: Russell Bedford Stefanou Mirchandani LLP's audit report on The Certo Group Corporation's December 31, 2005 financial statements states that the Company's recurring losses raise substantial doubts about its ability to continue as a going concern. The Company incurred losses of \$2,874,187 and \$56,790 for the years ended December 31, 2005 and 2004, respectively. The auditor also points out that the Company's current liabilities exceeded its current assets by \$1,601,165 as of December 31, 2005.

Intellectual Property: The Company has registered its corporate logo as a service mark on April 5, 2005, with the United States Patent and Trademark Office; and trademarks for the trade names LA Café and L.A. Food Services have been granted. [SEC Filing 10-KSB 05-01-07]

Description: Certo is a food service company, specializing in the exclusive management of in-house cafeterias, vending, catering and office coffee services to large corporate and institutional clients.

Officers: Dominic Certo (Pres., CEO & Dir.); George Kaden (CFO)

Auditor: Russell Bedford Stefanou Mirchandani LLP

Securities: 17,697,740 common shares outstanding as of December 31, 2005.

Notes: There is currently no public market for the Company's common stock

[Return to top](#)

**Prospector
Profile
07.0900**

The Enlightened Gourmet, Inc.

1028 Boulevard #319
West Hartford, CT 06119
(203) 230-9930

NAICS		311000
Description		Food Manufacturing
Employees		2
Revenue	(mil)	\$1.30
Income	(mil)	(\$2.60)
Assets	(mil)	\$0.68
Liability	(mil)	\$2.33
(for the year ended 12/31/2006)		

Category: Audit Concerns

Event: Mahoney Sabol & Company expressed substantial doubt on the Company's ability to continue as a going concern after auditing its financial statements. The Company is presently still dependent upon additional capital to continue its operations because its working capital is insufficient to maintain its operations. The auditor also adds that the Company needs to raise capital to pay for the various shareholder notes that are currently in default.

Intellectual Property: The Company's intellectual property consists of a proprietary recipe and manufacturing process. The Company decided not to seek a patent for this recipe and the time to seek patent protection for its process and recipe has passed. The Company believes that by treating the recipe and manufacturing process as a trade secret, it will afford greater protection than a patent, which would become public knowledge. The Company has filed an application with the United States Patent and Trademark Office to register the trademark Absolutely Free™. [SEC Filing 10-KSB 04-17-07]

Description: The Company is in the business of developing, marketing and selling food products.

Officers: Alexander L. Bozzi, III (Chair, COO & Chief Accounting Officer); Alexander L. Bozzi, IV (Sec.); Ronald A. Boyle (VP); Geno Celella (Dir.)

Auditor: Mahoney Sabol & Company

Securities: 89,926,500 common shares outstanding as of March 1, 2007.

[Return to top](#)

**Prospector
Profile
07.0901**

The Flooring Zone, Inc.

3219 Glynn Avenue
Brunswick, GA 31520
(912) 264-0505

NAICS	423310
Description	Flooring Products Retailer
Employees	5
Revenue (mil)	\$2.33
Income (mil)	(\$0.83)
Assets (mil)	\$0.43
Liability (mil)	\$2.79
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Mantyla McReynolds states in its audit report that The Flooring Zone, Inc. will need additional working capital to service debt and fund planned activities, which raises substantial doubt about the Company's ability to continue as a going concern. The Company has not generated sufficient revenue from operations to meet operating expenses, has accumulated deficit of \$3,002,667 since inception and has a negative working capital of \$1,219,346.

Intellectual Property: The Company has registered marks with the U.S. Trademark Office including: "The Flooring Zone" and "Save A Comma." [SEC Filing 10-KSB 04-17-07]

Description: The Company provides retail floor covering products and services in the United States.

Officers: Michael J. Carroll (Interim Pres., CEO, CFO & Dir.); Joel Arline (Dir.)

Auditor: Mantyla McReynolds

Securities: Common Stock-Symbol FZON.OB; OTC BB;
19,569,750 common shares outstanding as of March 30, 2007.

[Return to top](#)

**Prospector
Profile
07.0902**

Titan Trading Analytics, Inc.

751, 815 – 8th Avenue
Calgary, Alberta, Canada T2P 3P2
(780) 438-1239

NAICS	511210
Description	Software Publishers
Revenue (mil)	\$0.00
Income (mil)	(\$3.61)
Assets (mil)	\$0.46
Liability (mil)	\$0.50
(for the year ended 10/31/2006)	

Category: Audit Concerns

Event: Collins Barrow Edmonton LLP states that several adverse conditions cast substantial doubt on the ability of Titan Trading Analytics, Inc. to continue as a going concern. The Company has incurred significant operating losses over the past several fiscal years, and has an accumulated deficit of \$9,399,397 as of October 31, 2006. The Company also has a working capital deficiency of \$104,593.

Intellectual Property: The Company's ability to compete effectively depends in part on the ability to protect its core software technology. The Company relies on the following for protection of technology: trade secrets; technical complexity; common law copyright and trademark protection; password protection; software encryption schemes; and the physical security of source code. It has not applied for patents to date under Canadian or United States law. Management believes there are patentable elements of the online trading analytics program and may decide to file for patent protection depending on financial resources available. [SEC Filing 20-F 05-01-07]

Description: The Company provides world-class trading tools to money managers, trading firms and traders.

Officers: Dr. Kenneth W. Powell (Pres., CEO & Dir.); Michael Gossland (Sec. & Chief Technology Officer); Michael Gossland (Dir.); Philip S. Carrozza (Dir.); Robert Roddick (Dir.); Dr. Harold Elke (Dir.)

Auditor: Collins Barrow Edmonton LLP

Securities: Common Stock-Symbol TTA.V; CDNX;
30,814,497 common shares outstanding as of October 31, 2006.

[Return to top](#)

**Prospector
Profile
07.0903**

Torbay Holdings, Inc.

140 Old Country Road, Suite 205
Mineola, NY 11501
(516) 747-5955

NAICS	533110
Description	Patent Leasing
Employees	2
Revenue (mil)	\$0.36
Income (mil)	(\$0.67)
Assets (mil)	\$0.15
Liability (mil)	\$0.44
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Weinberg & Company, P.A. notes that Torbay Holdings, Inc. had a net loss of \$668,210 and a negative cash flow from operations of \$167,808 for the year ended December 31, 2006. In addition, it has a working capital deficiency of \$342,480 and a stockholders' deficiency of \$291,285 as of December 31, 2006. The auditor states that these factors raise substantial doubt about the Company's ability to continue as a going concern.

Intellectual Property: The Company holds a U.K. utility patent (No. BG2328496) on the AirO2bic Mouse and has applied for a U.S. patent on this product. Patent applications on the AirO2bic Mouse have also been made in other countries. In the United States, the Company has been granted, and holds, a utility patent No 7,145,548 entitled "Biomechanical Low Load Computer Mouse" on December 5, 2006. It has applied for an additional United States utility patent on its clickless web software, further mouse and keyboard designs and software that prescribes relaxation techniques on microprocessor controlled devices. [SEC Filing 10-KSB 05-02-07]

Description: The Company develops anti-fatigue tools and technologies in the United States.

Officers: Alexander Gordon Lane (Chair & Sec.); William Thomas Large (Pres., CEO & Dir.); Thomas A. Marchant (Dir.)

Auditor: Weinberg & Company, P.A.

Securities: Common Stock-Symbol TRBY.OB; OTC BB;
152,837,900 common shares outstanding as of April 10, 2007.

[Return to top](#)

**Prospector
Profile
07.0904**

Town Sports International Holdings, Inc.

888 Seventh Avenue
New York, NY 10106
(212) 246-6700

NAICS	713940
Description	Fitness Centers
Employees	8,600
Revenue (mil)	\$433.08
Income (mil)	\$4.65
Assets (mil)	\$423.53
Liability (mil)	\$441.36
(for the year ended 12/31/2006)	

Category: Loss/Deficit

Event: Town Sports International Holdings, Inc., reported a \$3,801,000 net loss on \$115,377,000 of revenues for the quarter ended March 31, 2007. The Company's balance sheet at March 31 showed \$436,394,000 in total assets and \$456,701,000 in total liabilities, resulting in a \$20,307,000 stockholders' deficit. The Company also reported strained liquidity with \$34,737,000 in total current assets and \$86,300,000 in total current liabilities.

Intellectual Property: The Company has registered various trademarks and service marks with the U.S. Patent and Trademark Office, including New York Sports Clubs, Washington Sports Clubs, Boston Sports Clubs, Philadelphia Sports Clubs, Companiesgetfit.com, Sports Clubs for Kids, “_____ Better.”, TSI and Town Sports International. [SEC Filing 10-K 03-12-07]

Description: The Company owns and operates fitness clubs in the Northeast and Mid-Atlantic regions of the U.S. Its clubs offer fitness area to accommodate cardiovascular and strength-training exercises; special purpose rooms for group fitness class instruction and other exercise programs; and other amenities, such as saunas and steam rooms; babysitting; and a retail shop.

Officers: Robert Giardina (CEO); Richard Pyle (CFO); Keith Alessi (Dir.); Paul Arnold (Dir.); Bruce Bruckmann (Dir.); Rice Edmonds (Dir.); Jason Fish (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock Symbol CLUB; NasdaqGM;
26,117,908 common shares outstanding as of May 1, 2007.
9-5/8% senior notes due April 15, 2011; 11% senior discount notes due February 2014.

[Return to top](#)

**Prospector
Profile
07.0905**

U.S. Helicopter Corporation

6 East River Piers, Downtown Manhattan Heliport
New York, NY 10004
(212) 248-2002

NAICS	481112
Description	Helicopter Transport Services
Employees	50
Revenue (mil)	\$1.42
Income (mil)	(\$9.62)
Assets (mil)	\$6.92
Liability (mil)	\$9.00
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Moore Stephens PC states that U.S. Helicopter Corporation has incurred substantial net operating losses and used substantial amounts of cash in operating activities. Since inception, the Company has incurred losses, has an accumulated deficit, and has experienced negative cash flows from operations. The auditor believes that these conditions raise substantial doubt about the Company's ability to continue as a going concern.

Intellectual Property: On March 21, 2006, the Company obtained registration of the mark "U.S. Helicopter" from the United States Patent and Trademark Office. [SEC Filing 10-KSB 04-17-07]

Description: The Company provides scheduled passenger helicopter service between metropolitan airports and surrounding city-based heliports under the name Metro-hop Airport Shuttle Service.

Officers: Dean C. Borgman (Chair); John G. Murphy (Pres., CEO & Dir.); Terence O. Dennison (SVP & COO); George J. Mehm, Jr. (SVP, Treas. & CFO); Donal F. McSullivan (SVP & Chief Marketing Officer); Gabriel Roberts (VP); Col. Clinton Pagano (Dir.); John Capozzi (Dir.); Christopher D. Brady (Dir.); George A. Fechter (Dir.); Edward J. Sherman (Dir.); Stephen T. Wills (Dir.)

Auditor: Moore Stephens PC

Securities: Common Stock-Symbol USHP.OB; OTC BB;
35,524,931 common shares outstanding as of March 31, 2007.

[Return to top](#)

**Prospector
Profile
07.0906**

Worldspace, Inc.

8515 Georgia Avenue
Silver Spring, MD 20910
(301) 960-1200

NAICS	515110
Description	Radio Broadcasting
Revenue (mil)	\$15.61
Income (mil)	(\$128.60)
Assets (mil)	\$568.65
Liability (mil)	\$2,172.00
(for the year ended 12/31/2006)	

Category: Loss/Deficit

Event: Worldspace, Inc. reported a net loss of \$35.5 million for the first quarter ended March 31, 2007, compared with a loss of \$29.2 million in the same period a year before. Revenue fell to \$3 million in the current quarter from \$3.5 million last year, due to lower equipment sales. As a result of its recurring losses, the Company has \$2,360.4 million in accumulated deficit and \$1,641.6 million in stockholder's deficit as of March 31, 2007.

Intellectual Property: The Company holds licenses from third parties to utilize patents covering various types of technology used in its system, including the digital compression technology. In addition, the Company has obtained patents and has patent applications pending with respect to its proprietary intellectual property. It also holds a blanket license granted by the Composers and Authors Society of Singapore to broadcast, perform, transmit, and otherwise use musical works. It also obtained a global license from the International Federation of the Phonographic Industry for the sound recording rights. Moreover, the Company has a similar license from the India equivalent Phonographic Performance Ltd. [SEC Filing 10-K 04-17-07]

Description: The Company engages in the design, development, construction, deployment, and financing of a satellite-based radio and data broadcasting service.

Officers: Noah A. Samara (Chair, Pres. & CEO); Sridhar Ganesan (EVP & CFO); Gregory B. Armstrong (Co-COO); Alexander P. Brown (Co-COO); Donald J. Frickel (EVP, Gen. Counsel & Sec.)

Auditor: Grant Thornton LLP

Securities: Common Stock-Symbol WRSP; NasdaqGM;
39,869,028 common shares outstanding as of April 13, 2007.

[Return to top](#)

**Prospector
Profile
07.0907**

XL Generation International, Inc.

Sumpfstrasse 32
6304 Zug, Switzerland
4141-723-1090

NAICS	238990
Description	Artificial Turfs

Revenue	(mil)	\$4.85
Income	(mil)	(\$17.75)
Assets	(mil)	\$0.20
Liability	(mil)	\$11.61

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Paritz & Company, P.A. expressed substantial doubt about the ability of XL Generation International, Inc. to continue as a going concern after auditing its financial statements. The Company has suffered recurring net losses and as of December 31, 2006, its current liabilities exceeded its current assets by \$11,441,625 and total liabilities exceeded its total assets by \$11,412,273.

Intellectual Property: WKF/5 Ltd. owns the worldwide commercial and manufacturing rights for the "XL technology," which consists of six patents. Of these six patents, one is patented in 38 countries, with patents pending in 6 more countries; another is patented in 16 countries, with patents pending in 28 more; two of these patents are pending in seven countries; and two of the six patents are pending in one country each. On January 1, 2005, the Company was granted a worldwide exclusive license to manufacture, assemble, sell, distribute and promote all the products covered by the Intellectual Property. [SEC Filing 10-KSB 04-17-07]

Description: The Company manufactures an artificial sport surface called "XL Turf." XL Turf is designed to reduce accidents while reproducing the natural feeling of playing on grass.

Officers: Alexander C. Gilmour (Chair); Michel St-Pierre (Acting CFO); Arthur Rawl (Dir.); Claude Pellerin (Dir.); Albert Beerli (Dir.)

Auditor: Paritz & Company, P.A.

Securities: Common Stock-Symbol XLGI.OB; OTC BB;
34,578,268 common shares outstanding as of March 31, 2007.

[Return to top](#)

**Prospector
Profile
07.0908**

XOMA Ltd.

2910 Seventh Street
Bekeley, CA 94710
(510) 204-7200

NAICS	325412
Description	Pharmaceuticals Mfg.
Employees	255
Revenue (mil)	\$29.50
Income (mil)	(\$51.84)
Assets (mil)	\$91.48
Liability (mil)	\$129.65
(for the year ended 12/31/2006)	

Category: Loss/Deficit

Event: XOMA Ltd. posted a \$15,928,000 net loss on \$12,252,000 in revenue for the quarter ended March 31, 2007, as compared with a \$20,603,000 net loss on \$5,604,000 in revenue for the same quarter last year. At March 31, 2007, the Company's balance sheet showed \$70,254,000 in total assets and \$76,177,000 in total liabilities, resulting to \$5,923,000 in stockholders' deficit.

Intellectual Property: The Company has established an extensive portfolio of patents and applications related to its bactericidal/permeability-increasing protein (BPI)-related products, including novel compositions, their manufacture, formulation, assay and use. The Company is the exclusive licensee of BPI-related patents and applications owned by New York University. It is also the exclusive licensee of BPI-related patents and applications owned by Incyte Corporation, including those related to endotoxin-associated uses of BPI. The Company has registered 11 patents related to its bacterial expression technology, including claims to novel promoter sequences, secretion signal sequences, compositions, methods for expression and secretion of recombinant proteins from bacteria, including immunoglobulin gene products, and improved methods and cells for expression of recombinant protein products. The Company has a patent application related to its mammalian expression technology and has registered a patent related to its HETTM technology. [SEC Filing 10-K 03-08-07]

Description: The Company discovers and develops commercialization antibodies, and other genetically-engineered protein products to treat immunological and inflammatory disorders

Officers: John L. Castello (Chair, Pres. & CEO); Patrick J. Scannon (EVP & Chief Biotechnology Officer); J. David Boyle II (VP-Finance & CFO); Christopher J. Margolin (VP, Gen. Counsel & Sec.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol XOMA; NasdaqGM;
131,690,515 common shares outstanding as of May 7, 2007.

[Return to top](#)